SCHEMBL13030213

SCHEMBL13030213

Cc1nc2ccc(NS(C)(=O)=O)cc2c(=O)[nH]1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.54
▸ HSD17B10 Q99714 2/20 0.54
▸ LMNA P02545 2/20 0.54
▸ PARG Q86W56 1/20 0.52
▸ ALDH1A1 P00352 2/20 0.50
▸ MAPT P10636 2/20 0.50
▸ HPGD P15428 2/20 0.50
▸ IP6K1 Q92551 1/20 0.50
▸ PARP1 P09874 1/20 0.50
▸ TNKS2 Q9H2K2 1/20 0.50
▸ NPC1 O15118 1/20 0.50
▸ USP2 O75604 1/20 0.50
▸ GLA P06280 1/20 0.50
▸ GAA P10253 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ MET P08581 7/20 0.49
▸ NPSR1 Q6W5P4 2/20 0.49
▸ POLB P06746 1/20 0.49
▸ KCNH2 Q12809 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13618942 0.82 KDM4E (0.59) KDM4EHSD17B10LMNAPARGALDH1A1
SCHEMBL13030212 0.77 KDM4E (0.50) KDM4EALDH1A1GAAMETKCNH2
SCHEMBL259298 0.75 GUSB (0.64) KDM4ELMNAMAPTTNKS2NPC1
SCHEMBL7263029 0.75 KDM4E (0.66) KDM4EHSD17B10LMNAPARGALDH1A1
SCHEMBL29535139 0.75 KDM4E (0.66) KDM4EHSD17B10LMNAPARGALDH1A1
SCHEMBL277606 0.74 MET (0.47) LMNAALDH1A1PARP1TNKS2NPC1
SCHEMBL29991941 0.74 PARG (0.61) KDM4EHSD17B10LMNAPARGALDH1A1
SCHEMBL18020459 0.73 IP6K1 (0.52) KDM4EHSD17B10LMNAALDH1A1MAPT
SCHEMBL16232298 0.73 KDM4E (0.59) KDM4EHSD17B10LMNAPARGALDH1A1
SCHEMBL3031632 0.72 EGLN1 (0.61) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100297073-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS CHIN ELBERT 2010-11-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297073-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS POLR2A, EIF2AK2, POLR2B KDM4E 1388/4885HSD17B10 1332/4885LMNA 2832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback